Previous 10 | Next 10 |
Rhythm Pharmaceuticals (NASDAQ: RYTM ) : Q2 GAAP EPS of -$0.71 beats by $0.12 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Appointed David Meeker, M.D., as President and Chief Executive Officer – -- FDA granted rare pediatric disease designations for setmelanotide for the treatment of POMC and LEPR deficiency obesities -- -- Submitted MAA to EMA for setmelanotide in POMC and LEPR deficiency ...
BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced the appointment of Joseph Shulman as the Com...
Rhythm Pharmaceuticals ( RYTM +0.8% ) appoints David Meeker, the company's chairman as the President and CEO, effective immediately. More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., the Chairman of Rhy...
-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing an...
The FDA has granted Rare Pediatric Disease Designatio n to Rhythm Pharmaceuticals' (NASDAQ: RYTM ) setmelanotide for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. More news on: Rhythm Pharmaceuticals, Inc., Healthcare s...
-- Company also announces positive data from eight supplemental patients, including four pediatric patients, enrolled in pivotal Phase 3 clinical trials; all achieved primary endpoint of 10 percent weight loss -- -- Setmelanotide was well-tolerated in long-term extension study with co...
BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (...
Rhythm Pharmaceuticals Reports Positive Phase 2 Data for Setmelanotide Rhythm Pharmaceuticals Inc. ( RYTM ) announced interim data from its Phase 2 study of Setmelanotide. Under this trial, healthy obese people were administered the weekly formulation of the drug candidate. The trial wa...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...